| 3.9 -0.35 (-8.24%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.25  |
1-year : | 6.27 |
| Resists | First : | 4.5 |
Second : | 5.36 |
| Pivot price | 4.42 |
|||
| Supports | First : | 3.09 |
Second : | 2.57 |
| MAs | MA(5) : | 4.37 |
MA(20) : | 4.39 |
| MA(100) : | 3.52  |
MA(250) : | 3.87 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 47.1 |
D(3) : | 56.2 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 9.5 | Low : | 1.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LRMR ] has closed above bottom band by 26.4%. Bollinger Bands are 124.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.21 - 4.24 | 4.24 - 4.26 |
| Low: | 3.8 - 3.84 | 3.84 - 3.87 |
| Close: | 3.85 - 3.9 | 3.9 - 3.94 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Tue, 14 Oct 2025
Larimar Therapeutics, Inc. Securities Lawsuit Investigation - Claim Depot
Tue, 14 Oct 2025
Larimar Therapeutics, Inc. Updates on Nomlabofusp Development - TradingView
Mon, 13 Oct 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - PR Newswire
Fri, 03 Oct 2025
Why Larimar Therapeutics (LRMR) Is Up After Positive Long-Term Results for Friedreich's Ataxia Therapy - Sahm
Thu, 02 Oct 2025
Oppenheimer Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Mon, 29 Sep 2025
100% of Friedreich's Ataxia Patients Hit Critical Protein Levels: Larimar's Drug Shows Disease-Modifying Potential - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 86 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 83.4 (%) |
| Shares Short | 8,940 (K) |
| Shares Short P.Month | 6,400 (K) |
| EPS | -1.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.1 % |
| Return on Equity (ttm) | -60.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -2.49 |
| PEG Ratio | 0 |
| Price to Book value | 2.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|